Profiling circulating DNA and RNA to identify mechanisms of therapeutic resistance and response in metastatic castration-resistant prostate cancer

Enzalutamide是一种强效激素治疗药物，可提高晚期前列腺癌男性患者的生存率。不幸的是，所有前列腺癌最终都会对Enzalutamide产生耐药性，并且并非所有男性最初都对治疗有反应。我将寻找预测哪些男性从enzalutamide治疗中获益的血液标志物，并试图了解enzalutamide耐药是如何发生的。这可能导致Enzalutamide的更有效使用，从而在晚期前列腺癌中获得更好的结局。

Enzalutamide is a powerful hormone treatment that improves survival for men with advanced prostate cancer. Unfortunately, all prostate cancers eventually become resistant to enzalutamide and not all men initially respond to treatment. I will look for blood markers that predict which men benefit from enzalutamide treatment and try to understand how resistance to enzalutamide occurs. This may lead to more effective use of enzalutamide resulting in better outcomes in advanced prostate cancer.